Cargando…

Development and Validation of a Novel Tool to Predict Model for End-Stage Liver Disease (MELD) Scores in Cirrhosis, Using Administrative Datasets

BACKGROUND: The Model for End-Stage Liver Disease (MELD) score predicts disease severity and mortality in cirrhosis. To improve cirrhosis phenotyping in administrative databases lacking laboratory data, we aimed to develop and externally validate claims-based MELD prediction models, using claims dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Tracey G, Schneeweiss, Sebastian, Wyss, Richard, Lu, Zhigang, Bessette, Lily G, York, Cassandra, Lin, Kueiyu Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024467/
https://www.ncbi.nlm.nih.gov/pubmed/36941978
http://dx.doi.org/10.2147/CLEP.S387253
_version_ 1784909108765261824
author Simon, Tracey G
Schneeweiss, Sebastian
Wyss, Richard
Lu, Zhigang
Bessette, Lily G
York, Cassandra
Lin, Kueiyu Joshua
author_facet Simon, Tracey G
Schneeweiss, Sebastian
Wyss, Richard
Lu, Zhigang
Bessette, Lily G
York, Cassandra
Lin, Kueiyu Joshua
author_sort Simon, Tracey G
collection PubMed
description BACKGROUND: The Model for End-Stage Liver Disease (MELD) score predicts disease severity and mortality in cirrhosis. To improve cirrhosis phenotyping in administrative databases lacking laboratory data, we aimed to develop and externally validate claims-based MELD prediction models, using claims data linked to electronic health records (EHR). METHODS: We included adults with established cirrhosis in two Medicare-linked EHR networks (training and internal validation; 2007–2017), and a Medicaid-linked EHR network (external validation; 2000–2014). Using least absolute shrinkage and selection operator (LASSO) with 5-fold cross-validation, we selected among 146 investigator-specified variables to develop models for predicting continuous MELD and relevant MELD categories (MELD<10, MELD≥15 and MELD≥20), with observed MELD calculated from laboratory data. Regression coefficients for each model were applied to the validation sets to predict patient-level MELD and assess model performance. RESULTS: We identified 4501 patients in the Medicare training set (mean age 75.1 years, 18.5% female, mean MELD=13.0), and 2435 patients in the Medicare validation set (mean age: 74.3 years, 31.7% female, mean MELD=12.3). Our final model for predicting continuous MELD included 112 variables, explaining 58% of observed MELD variability; in the Medicare validation set, the area-under-the-receiver operating characteristic curves (AUC) for MELD<10 and MELD≥15 were 0.84 and 0.90, respectively; the AUC for the model predicting MELD≥20 (using 27 variables) was 0.93. Overall, these models correctly classified 77% of patients with MELD<10 (95% CI=0.75–0.78), 85% of patients with MELD≥15 (95% CI=0.84–0.87), and 87% of patients with MELD≥20 (95% CI=0.86–0.88). Results were consistent in the external validation set (n=2240). CONCLUSION: Our MELD prediction tools can be used to improve cirrhosis phenotyping in administrative datasets lacking laboratory data.
format Online
Article
Text
id pubmed-10024467
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-100244672023-03-19 Development and Validation of a Novel Tool to Predict Model for End-Stage Liver Disease (MELD) Scores in Cirrhosis, Using Administrative Datasets Simon, Tracey G Schneeweiss, Sebastian Wyss, Richard Lu, Zhigang Bessette, Lily G York, Cassandra Lin, Kueiyu Joshua Clin Epidemiol Original Research BACKGROUND: The Model for End-Stage Liver Disease (MELD) score predicts disease severity and mortality in cirrhosis. To improve cirrhosis phenotyping in administrative databases lacking laboratory data, we aimed to develop and externally validate claims-based MELD prediction models, using claims data linked to electronic health records (EHR). METHODS: We included adults with established cirrhosis in two Medicare-linked EHR networks (training and internal validation; 2007–2017), and a Medicaid-linked EHR network (external validation; 2000–2014). Using least absolute shrinkage and selection operator (LASSO) with 5-fold cross-validation, we selected among 146 investigator-specified variables to develop models for predicting continuous MELD and relevant MELD categories (MELD<10, MELD≥15 and MELD≥20), with observed MELD calculated from laboratory data. Regression coefficients for each model were applied to the validation sets to predict patient-level MELD and assess model performance. RESULTS: We identified 4501 patients in the Medicare training set (mean age 75.1 years, 18.5% female, mean MELD=13.0), and 2435 patients in the Medicare validation set (mean age: 74.3 years, 31.7% female, mean MELD=12.3). Our final model for predicting continuous MELD included 112 variables, explaining 58% of observed MELD variability; in the Medicare validation set, the area-under-the-receiver operating characteristic curves (AUC) for MELD<10 and MELD≥15 were 0.84 and 0.90, respectively; the AUC for the model predicting MELD≥20 (using 27 variables) was 0.93. Overall, these models correctly classified 77% of patients with MELD<10 (95% CI=0.75–0.78), 85% of patients with MELD≥15 (95% CI=0.84–0.87), and 87% of patients with MELD≥20 (95% CI=0.86–0.88). Results were consistent in the external validation set (n=2240). CONCLUSION: Our MELD prediction tools can be used to improve cirrhosis phenotyping in administrative datasets lacking laboratory data. Dove 2023-03-14 /pmc/articles/PMC10024467/ /pubmed/36941978 http://dx.doi.org/10.2147/CLEP.S387253 Text en © 2023 Simon et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Simon, Tracey G
Schneeweiss, Sebastian
Wyss, Richard
Lu, Zhigang
Bessette, Lily G
York, Cassandra
Lin, Kueiyu Joshua
Development and Validation of a Novel Tool to Predict Model for End-Stage Liver Disease (MELD) Scores in Cirrhosis, Using Administrative Datasets
title Development and Validation of a Novel Tool to Predict Model for End-Stage Liver Disease (MELD) Scores in Cirrhosis, Using Administrative Datasets
title_full Development and Validation of a Novel Tool to Predict Model for End-Stage Liver Disease (MELD) Scores in Cirrhosis, Using Administrative Datasets
title_fullStr Development and Validation of a Novel Tool to Predict Model for End-Stage Liver Disease (MELD) Scores in Cirrhosis, Using Administrative Datasets
title_full_unstemmed Development and Validation of a Novel Tool to Predict Model for End-Stage Liver Disease (MELD) Scores in Cirrhosis, Using Administrative Datasets
title_short Development and Validation of a Novel Tool to Predict Model for End-Stage Liver Disease (MELD) Scores in Cirrhosis, Using Administrative Datasets
title_sort development and validation of a novel tool to predict model for end-stage liver disease (meld) scores in cirrhosis, using administrative datasets
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024467/
https://www.ncbi.nlm.nih.gov/pubmed/36941978
http://dx.doi.org/10.2147/CLEP.S387253
work_keys_str_mv AT simontraceyg developmentandvalidationofanoveltooltopredictmodelforendstageliverdiseasemeldscoresincirrhosisusingadministrativedatasets
AT schneeweisssebastian developmentandvalidationofanoveltooltopredictmodelforendstageliverdiseasemeldscoresincirrhosisusingadministrativedatasets
AT wyssrichard developmentandvalidationofanoveltooltopredictmodelforendstageliverdiseasemeldscoresincirrhosisusingadministrativedatasets
AT luzhigang developmentandvalidationofanoveltooltopredictmodelforendstageliverdiseasemeldscoresincirrhosisusingadministrativedatasets
AT bessettelilyg developmentandvalidationofanoveltooltopredictmodelforendstageliverdiseasemeldscoresincirrhosisusingadministrativedatasets
AT yorkcassandra developmentandvalidationofanoveltooltopredictmodelforendstageliverdiseasemeldscoresincirrhosisusingadministrativedatasets
AT linkueiyujoshua developmentandvalidationofanoveltooltopredictmodelforendstageliverdiseasemeldscoresincirrhosisusingadministrativedatasets